3 and 6 months on the treatment.

Nine of 12 patients showed 2-point improvements in their QST scores, four subjects in the SB-509 treated leg alone, three subjects in both legs and two subjects were treated in the placebo leg alone. Studies leg. These bilateral clinical effects are ongoing and include measurements of serum VEGF as well as retrograde or neurovascular transport of SB-509 and / or VEGF.. About the SB-509 Clinical ProgramPhase 1aAll subjects in the Phase 1a dose – escalation study received a single treatment of SB-509 in one leg and placebo in the other leg and were at 1, 3 and 6 months on the treatment.

About SB -509 – is SB-509 as an injectable formulation of plasmid DNA a ZFP a ZFP TF, to the VEGF-A gene encodes administered upregulate. VEGF-A has been shown that direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model recently published in the journal Diabetes, SB-509 has been proven effective protection motor and sensory nerve function from disease-induced nerve damage.The warning comes as a minister of the biggest health strategy up unveil today, targeting smoking, obesity and sexual health, preparing BMA News reports.